Clinical Trial Update: Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and safety study of dolutegravir and rilpivirine (JULUCA) 50 mg/25 mg in healthy Japanese subjects completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Juluca (dolutegravir + rilpivirine)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2020-07-14